Endpoint

Malondialdehyde (circulating)

The dialdehyde of malonic acid.

Definition from MeSH (D008315), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

CAT:outcome/malondialdehyde-circulatingreported in micromol/L19 findings from 11 compounds

Open in the graph

What moved it

How to read these marks

19 findings · 11 compounds · 5 null · by evidence strength

Compound	Direction	Findings	Strongest evidence
curcumin	down	5	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
melatonin	down 2 · no effect 1	3	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
coenzyme Q10	no effect 1 · down 1	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
resveratrol	up 1 · down 1	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Rhodiola rosea	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Vitis vinifera	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Zn(2+)	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
calciol	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
crocin-1	no effect	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
Withania somnifera	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
L-glutamine	down	1	Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.

Reported to move it

14 findings

resveratrol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“After 12 weeks, MDA levels increased significantly in both groups, with a larger rise in the RES group, resulting in significantly higher MDA levels in the RES group compared to the control at the end of the study.”
Quoted verbatim from Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?.
Study

RCT
Participants

40
Duration

3 months
Dose

400 mg/day liposomal resveratrol via enteral access, in two doses
Population

adults with head and neck cancer on home enteral nutrition; open-label, resveratrol plus HEN versus HEN alone
Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?2025PMID:39940362Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4
“Conversely, MDA levels, a marker of lipid peroxidation, were significantly lower in the curcumin group compared with placebo (1.29 [1.05–1.58] vs. 2.45 [2.14–2.77], p < 0.001), corresponding to a large effect size ( r = 0.85, 95% CI: 0.77–0.91).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
Study

RCT
Duration

12 months
Dose

Curcumin 1500 mg/day orally for 12 months
Population

Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry fundedPermalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4
“In parallel, curcumin treatment led to a significant reduction in malondialdehyde (MDA) levels—a key biomarker of oxidative stress—across the same time points (Table 3).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial..
Study

RCT
Dose

1500 mg/day curcuminoid extract
Population

obese adults with type 2 diabetes mellitus, secondary endpoint
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4
“In contrast, nanocurcumin significantly increased total antioxidant capacity (SMD: 1.60; 95% CI: 0.93 to 2.31) and reduced malondialdehyde levels (SMD: -1.93; 95% CI: -3.19 to -0.66), indicating a robust antioxidative effect.”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials..
Study

meta-analysis
Participants

153
Population

adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
melatonin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“The reduction in serum MDA in the melatonin group was also statistically significant when compared to the placebo group ( P = 0.03; Table 3).”
Quoted verbatim from Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial..
Study

RCT
Dose

Melatonin 5 mg tablet, one tablet nightly one hour before bedtime, for 10 weeks
Population

Adults aged 19-75 with chronic kidney failure on continuous ambulatory peritoneal dialysis, four PD centres in Iran; 46 recruited, 44 analysed (22 melatonin, 22 placebo) after one exclusion per group for peritonitis; serum MDA was a pre-specified PRIMARY outcome; double-blind, placebo-controlled; MDA measured in serum by colorimetric commercial kit (ZellBio GmbH), intra-assay CV 5.5%; between-group comparison of change from baseline at week 10
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.2025PMID:41125682Industry fundedPermalink
melatonin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“The meta-analysis indicated that melatonin supplementation considerably lowered serum MDA levels (WMD: −1.54 μmol/L, 95% CI: −2.07, −1.01) and markedly increased serum TAC levels (WMD: 0.15 mmol/L, 95% CI: 0.08, 0.22) in the melatonin-treated group versus the untreated group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis..
Study

meta-analysis
Dose

0.3-100 mg/day oral
Population

adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -1.54 mean difference, 95% CI -2.07 to -1.01
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249Permalink

Show the remaining 8

Zn(2+) — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Four studies showed significantly lower MDA with zinc supplementation (SMD = −0.76; 95% CI −1.34 to −0.18; p = 0.010), with substantial heterogeneity (I 2 = 77%).”
Quoted verbatim from Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials..
Study

meta-analysis
Population

Adults and children with type 1 or type 2 diabetes, gestational diabetes or prediabetes in 18 pooled RCTs of zinc supplementation against placebo or standard care
Effect -0.76 standardised mean difference, 95% CI -1.34 to -0.18
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42594341Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4
“Furthermore, synthesized data from three studies indicated that curcumin was associated with reduced levels of MDA, a marker of lipid peroxidation (MD = -1.99, 95% CI = -3.22 to -0.77, p = 0.001;.”
Quoted verbatim from Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study..
Study

animal · not in humans
Population

ovariectomized/GIOP/metabolic osteoporosis rodent models, meta-analysis of 3 studies
Effect -1.99 mean difference, 95% CI -3.22 to -0.77
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.2026PMID:42656268Permalink
calciol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin..
Study

RCT
Population

NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.2023PMID:37667938Permalink
coenzyme Q10 — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“CoQ10 supplementation, in the tested range of doses, was shown to reduce MDA concentrations, and increase TAC and antioxidant defense system enzymes.”
Quoted verbatim from Coenzyme Q10 supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials..
Study

meta-analysis
Population

participants in randomized clinical trials of CoQ10 supplementation
Coenzyme Q10 supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials.2020PMID:32583356Permalink
resveratrol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Resveratrol treatment significantly decreased TNF-α (P < 0.001), and MDA (P < 0.001) compared to the placebo.”
Quoted verbatim from Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial..
Study

RCT
Duration

8 weeks
Dose

500 mg/day
Population

patients with multiple sclerosis (MS)
Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.2025PMID:39565038Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4
“There was a significant reduction in circulating MDA concentrations (SMD = -0.769, 95% CI: -1.059 to -0.478) and a significant increase in SOD activity (SMD = 1.084, 95% CI: 0.487 to 1.680) following curcumin supplementation.”
Quoted verbatim from Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress..
Study

meta-analysis
Population

adults in RCTs of curcumin supplementation (>=4 weeks) assessing oxidative-stress biomarkers
Effect -0.769 standardised mean difference, 95% CI -1.059 to -0.478
Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress.2018PMID:30527253Permalink
Withania somnifera — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“All doses of AE (SD + A1 to SD + A4) reduced serum, liver, and brain MDA levels compared to those in non-supplemented rats (p < 0.01, Figure 4).”
Quoted verbatim from A Novel Ashwagandha (Withania somnifera) Formulation Mitigates Sleep Deprivation-Induced Cognitive Impairment and Oxidative Stress in a Rat Model..
Study

animal · not in humans
Duration

4 weeks
Dose

15 or 30 mg/kg of 1.5% extract, or 5.5 or 11 mg/kg of 8% extract, once daily by oral gavage
Population

Male Sprague-Dawley rats (n = 7 per group) subjected to sleep deprivation for 4 weeks; comparison is against sleep-deprived rats given saline; all four AE dose groups pooled in the sentence
A Novel Ashwagandha (Withania somnifera) Formulation Mitigates Sleep Deprivation-Induced Cognitive Impairment and Oxidative Stress in a Rat Model.2025PMID:40427603An author is affiliated with a producerPermalink
L-glutamine — decreases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“Serum concentrations of malondialdehyde, nitric oxide synthase and nitric oxide were significantly higher in PCOS group (P < 0.01) compared with the control group, and significantly decreased to the comparative levels of control group with supplementation of 0.5 g/kg glutamine (P < 0.01).”
Quoted verbatim from The effect of glutamine on Dehydroepiandrosterone-induced polycystic ovary syndrome rats..
Study

animal · not in humans
Dose

0.5 g/kg, intraperitoneal, twice on the morning after the last DHEA injection
Population

Female Sprague-Dawley rats, DHEA-induced PCOS model, 0.5 g/kg glutamine dose
The effect of glutamine on Dehydroepiandrosterone-induced polycystic ovary syndrome rats.2020PMID:32386521Permalink

Measured, no effect detected

5 findings

coenzyme Q10 — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“As shown in Table 2, the between-group comparison revealed no significant difference between CoQ10 and placebo groups at the end of the study for MDA (P = 0.692), SOD activity (P = 0.633), and TAC (P = 0.865).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial..
Study

RCT
Participants

52
Duration

10 days
Dose

100 mg three times a day after meals, total 300 mg/day
Population

Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600Permalink
melatonin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Also, the MLT group demonstrated marginal reduction in MDA compared to placebo group (F = 3.046, p = 0.092, partial η2 = 0.095), revealing a trend towards decreased oxidative stress that did not reach statistical significance.”
Quoted verbatim from Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial..
Study

RCT
Duration

3 months
Dose

5 mg oral melatonin once daily 1 h before bedtime for 12 weeks
Population

children on chronic haemodialysis; primary endpoint, ANCOVA adjusted for baseline MDA and antihypertensive use; serum MDA by ELISA
Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.2026PMID:41565787Permalink
Vitis vinifera — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“According to the meta-analysis of seven RCTs, GPCP had no significant impact on MDA levels (WMD = − 0.178 μmol/L; 95% CI: − 0.46, 0.11; P = 0.22).”
Quoted verbatim from The effect of grape products containing polyphenols on oxidative stress: a systematic review and meta-analysis of randomized clinical trials..
Study

meta-analysis
Population

Adults in seven pooled randomized trials of grape products containing polyphenols (grape extract, grape powder, juice, raisin, resveratrol, red wine), healthy and unhealthy participants combined
Effect -0.178 mean difference, 95% CI -0.46 to 0.11
The effect of grape products containing polyphenols on oxidative stress: a systematic review and meta-analysis of randomized clinical trials.2021PMID:33712024Industry fundedPermalink
Rhodiola rosea — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“No significant differences were observed in MDA or CK levels either within or between groups after 28 days of continuous RHO supplementation.”
Quoted verbatim from The Effect of Short-Term Rhodiola rosea Supplementation on Simulated Game Time, Perceived Fatigue, and Performance in Basketball Players..
Study

RCT
Duration

4 weeks
Dose

2.4 g/day, taken fasted 30 min before breakfast and lunch, for 28 days
Population

48 professional male basketball players, Rhodiola group versus control group given empty capsules; plasma MDA by TBARS after 28 days
The Effect of Short-Term Rhodiola rosea Supplementation on Simulated Game Time, Perceived Fatigue, and Performance in Basketball Players.2025PMID:41373984Industry fundedPermalink
crocin-1 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly.”
Quoted verbatim from Crocin Supplementation on Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Population

Adults supplemented with crocin in pooled randomised clinical trials
Crocin Supplementation on Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis.2025PMID:39632602Permalink

How it is measured

Malondialdehyde concentration in plasma, serum or whole blood, by thiobarbituric-acid-reactive-substances colorimetry or by HPLC. The assay is recorded with each finding and is not optional: TBARS reads systematically higher than HPLC because it captures other aldehydes.

Sources cited

19 papers

Subject: malondialdehyde (circulating)
Findings: 19
Papers: 19